|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
One of every 3 patients with T2DM and CKD received inappropriate dosing of DPP-4 inhibitor, which was associated with high risk of emergency department visits, severe hypoglycemia, and mortality.
|
31812252 |
2020 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.
|
30418475 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Sitagliptin and shock wave-supported peripheral blood derived endothelial progenitor cell therapy effectively preserves residual renal function in chronic kidney disease in rat-role of dipeptidyl peptidase 4 inhibition.
|
30841422 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the effect of treatment with the dipeptidyl peptidase-4 inhibitor, sitagliptin, on adenine-induced chronic kidney disease (CKD).
|
30553193 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase type 4 (DPP-4) inhibitors were reported to have beneficial effects in experimental models of chronic kidney disease.
|
30979564 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the albuminuria-lowering effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the effect of dapagliflozin-saxagliptin on glycaemic control in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.
|
30992195 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study assessed the association between dipeptidyl peptidase-4 inhibitors (DPP-4i) and the risk of cardiovascular events in patients with type 2 diabetes mellitus with or without chronic kidney disease (CKD).
|
31112536 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DPP-4 activity was increased in CKD.Western blot density of GLP-1R in renal cortex extracts revealed increased abundance 2 weeks after 5/6 nephrectomy, followed by a decrease at 8 weeks.
|
30823876 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension.
|
30774748 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cardiac dysfunction is one of the main outcomes of chronic kidney disease (CKD); however, the effects of DPPIV inhibition on cardiac impairment during CKD progression remain elusive.
|
31010001 |
2019 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
More than a third of DPP4-i patients with CKD stage 3b or higher were prescribed doses not concordant with DPP4-i label dosage recommendations.
|
29231750 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This analysis of real-world data aimed to (a) determine the proportion of Type II diabetes (T2DM) patients treated with metformin or dipeptidyl peptidase-4 inhibitors (DPP-4i) that require dose adjustment or therapy discontinuation due to chronic kidney disease (CKD), and (b) to assess the time required to dose adjustment from the time of worsening of CKD.
|
29611727 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD).
|
30593182 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition.
|
30343892 |
2018 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The PubMed, Embase (via Ovid), and Cochrane Central databases were searched for papers regarding the effects of DPP-4 inhibitors in CKD patients published before 1 August 2016.
|
28266136 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to evaluate long-term cost-effective of dipeptidyl peptidase-4 (DPP-4) inhibitor monothearpy vs sulfonylurea (SFU) monotherapy in people with T2DM and CKD.
|
27645706 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
• Here, a comprehensive analysis of serum peptidase activities in patients with different stages of chronic kidney disease (CKD) is presented, with special emphasis given to RAS peptidases • The serum activities of the peptidases angiotensin I-converting enzyme 2 and dipeptidyl peptidase 4 were identified as closely associated with kidney function, specifically with the estimated glomerular filtration rate.
|
28038565 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We reviewed 12 studies with 4,403 patients with CKD and 239 on dialysis, finding a mean weighted decline in HbA1C of -0.48 (95% CI -0.61 to -0.35) with DPP-4 inhibitor therapy compared to placebo.
|
28178698 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
|
28686724 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
DPP-4 inhibitors may therefore be promising therapeutic choices even for nondiabetic CKD patients.
|
28118775 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
|
28122713 |
2017 |
|
Chronic Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The dose of DPP-4 inhibitors should be reduced (except for linagliptin), whereas both the efficacy and safety of SGLT2 inhibitors are questionable in presence of CKD.
|
23461781 |
2013 |
|
Chronic Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to identify the most appropriate treatment for cardiac dysfunction associated with CKD.
|
22125632 |
2011 |